Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Transl Neurodegener 14(1):67
AOD-9604 does not affect the hypothalamic-pituitary axis, so there is no negative feedback loop to blunt the response over time
The medicinal-chemistry programme that produced cagrilintide, described by Kruse and colleagues in the Journal of Medicinal Chemistry in 2021, addressed this by re-engineering the amylin backbone with structural elements borrowed from calcitonin (a related, non-aggregating peptide) and attaching a fatty-acid side chain that enables reversible binding to serum albumin [1]
A 2022 study co-encapsulated GHK-Cu with acetyl tetrapeptide-3 and myristoyl pentapeptide-4 in nanoliposomes
